LOXO Loxo Oncology, Inc.

+1  (2%)
Previous Close 48.28
Open 48.27
Price To book 8.04
Market Cap 1.29B
Shares 26,146,000
Volume 216,867
Short Ratio 14.44
Av. Daily Volume 222,111

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced February 21, 2017 that trial enrollment has been completed with Phase 2 data due 2H 2017. NDA filing late 2017 or early 2018. Late breaker ASCO June 3, 2017. Abstract LBA2501.
Larotrectinib (LOXO-101) - NAVIGATE
Solid tumors that harbor a TRK fusion.

Latest News

  1. Loxo Oncology Announces Acceptance of Larotrectinib Oral Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
  2. Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017
  3. Loxo Oncology Announces Larotrectinib Pan-TRK IHC Companion Diagnostic Collaboration with Ventana Medical Systems, Inc., a member of the Roche Group
  4. 5 Stocks The Best Performing Hedge Funds Are Piling Into
  5. After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead
  6. Loxo reports 4Q loss
  7. Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial Results
  8. Should You Sell Loxo Oncology (LOXO) Before Earnings?
  9. Loxo Oncology to Present at Cowen and Company 37th Annual Health Care Conference
  10. Loxo Oncology to Announce Fourth Quarter and Year-End 2016 Financial Results
  11. Loxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis
  12. Purcell Julie & Lefkowitz LLP is Investigating Loxo Oncology, Inc. for Potential Breaches of Fiduciary Duty by its Board of Directors
  13. Huge Michael Dell Purchase Highlights Insider Buying: Dell Technologies, Accelerate Diagnostics, Loxo Oncology and More
  14. One of The Largest Hedge Funds In The World Is Betting On Loxo Oncology Inc. (LOXO)
  15. Can Loxo Oncology Inc (LOXO) Candidate Larotrectinib Pass Regulatory Test?
  16. Loxo Oncology (LOXO) Surges: Stock Moves 25.8% Higher
  17. Why Loxo Oncology Stock Soared As Much As 36% Today